Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

CVRx Q3 2026 Results: Net Loss of $14.2M, Loss Widens

For the nine months ended September 30, 2026, CVRx reported revenue of $44.3 million, an increase from $40.6 million in the prior year period. Despite the revenue growth, the company reported a net loss of $41.3 million for the first nine months of 2026, consistent with the prior year, as it continues to invest heavily in selling, general, and administrative expenses to support its Barostim product.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue13.814.7
Gross profit12.012.8
Profit before tax-14.2-12.9
Net income-14.2-12.9
EPS (diluted, $ a share)$-0.52$-0.49

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-5.8%
Gross margin86.7%
Operating margin-94.3%
Source

10-Q filed with the SEC, NASDAQ: CVRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CVRx, Inc.: key numbers

Share price
$0.6130Close, Nov 16
Market cap
$17.5M
Shares outstanding
28.49MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CVRx, Inc.

All →
4:16 PM ET 8-K
Financial Results

CVRx Financial Results

CVRx reported third quarter 2026 financial results, with total revenue of $13.8 million, a 6% decrease year-over-year. The decline was primarily attributed to lower sales force productivity and challenges with a major payer, though the company expanded its U.S. active implanting centers to 262.

“While we recognize there is more work ahead, we remain encouraged by the progress we are making on key strategic initiatives, including the expansion of Medicare Advantage coverage and the clinical evidence released at HFSA. With new Medicare Advantage coverage policies, BENEFIT-HF enrolling, and continued focus on commercial execution, we are confident in our ability to bring this therapy to more patients living with heart failure.”

Kevin Hykes, President and Chief Executive Officer of CVRx
4:13 PM ET 8-K
Executive Compensation

CVRx Executive Compensation

CVRx, Inc. appointed John Landry as Chief Financial Officer, effective October 12, 2026, succeeding Jared Oasheim. Mr. Landry's compensation package includes a $500,000 base salary, a 50% target cash incentive, and initial equity awards (75% options, 25% RSUs) representing 0.80% of total common shares outstanding.

Counterparty
John Landry

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.